Estrogen and progesterone receptors in epithelial ovarian tumours

Abstract

and malignant epithelial ovarian tumours differ in respect of receptor status/content. This study was undertaken to determine the influence of histological type of different epithelial ovarian cancers on receptor status. Furthermore, we analyzed differences in receptor status in cases with more than one location of the ovarian tumour in the same patient and differences in receptor content in benign, borderline and malignant ovarian tumours. MATERIALS AND METHODSBetween 01.05.1986 and 01.03.1989 43 patients with histologically proven primary epithelial ovarian tumours entered this study. The median age was 59 years (range 29-85).Tumour specimens were obtained at first laparotomy. The specimens were received immediately from the theatre and the tumour tissue was dissected free of 916

Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity

“…According to previous reports, ER‐α was expressed in ECO and serous adenocarcinoma 12 . We examined the expression of ER‐α in NOE cells.…”

“…According to previous reports, ER-α was expressed in ECO and serous adenocarcinoma. 12 We examined the expression of ER-α in NOE cells. Figure 6 shows that the expression level of ER-α in NOE cells was higher than that of HEY and RMG-II cells.…”

Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity

“…According to previous reports, ER‐α was expressed in ECO and serous adenocarcinoma 12 . We examined the expression of ER‐α in NOE cells.…”

“…According to previous reports, ER-α was expressed in ECO and serous adenocarcinoma. 12 We examined the expression of ER-α in NOE cells. Figure 6 shows that the expression level of ER-α in NOE cells was higher than that of HEY and RMG-II cells.…”

Expressions of Estrogen and Progesterone Receptorsin Epithelial Ovarian Cancer

“…Other studies that attempted to evaluate the prognostic role of ER and PR in combination could not demonstrate an additional benefit of ER+ or ERj expression to the PR+ tumors. 7,11,13,22,26 Different findings on ER/PR expressions and their association with survival in each study might lie on many factors, such as the number of patients studied, the follow-up time, or the heterogeneous patient population wherein some studies included tumors of low malignant potential and others included only patients with advanced-stage diseases. 8,9,12,17 Furthermore, various proportions of tumors with aggressive behavior of clear cell carcinoma or high-grade tumors in these studies may contribute further to the difference.…”

Hormonal therapy in ovarian cancer

“…ER are expressed in 61% to 79% of EOC (71,101,102) . Serous and endometrioid types have the highest ER expression (71,103) .…”

Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity

“…According to previous reports, ER‐α was expressed in ECO and serous adenocarcinoma 12 . We examined the expression of ER‐α in NOE cells.…”

“…According to previous reports, ER-α was expressed in ECO and serous adenocarcinoma. 12 We examined the expression of ER-α in NOE cells. Figure 6 shows that the expression level of ER-α in NOE cells was higher than that of HEY and RMG-II cells.…”

Expressions of Estrogen and Progesterone Receptorsin Epithelial Ovarian Cancer

“…Other studies that attempted to evaluate the prognostic role of ER and PR in combination could not demonstrate an additional benefit of ER+ or ERj expression to the PR+ tumors. 7,11,13,22,26 Different findings on ER/PR expressions and their association with survival in each study might lie on many factors, such as the number of patients studied, the follow-up time, or the heterogeneous patient population wherein some studies included tumors of low malignant potential and others included only patients with advanced-stage diseases. 8,9,12,17 Furthermore, various proportions of tumors with aggressive behavior of clear cell carcinoma or high-grade tumors in these studies may contribute further to the difference.…”

Hormonal therapy in ovarian cancer

“…ER are expressed in 61% to 79% of EOC (71,101,102) . Serous and endometrioid types have the highest ER expression (71,103) .…”

Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity

“…According to previous reports, ER‐α was expressed in ECO and serous adenocarcinoma 12 . We examined the expression of ER‐α in NOE cells.…”

“…According to previous reports, ER-α was expressed in ECO and serous adenocarcinoma. 12 We examined the expression of ER-α in NOE cells. Figure 6 shows that the expression level of ER-α in NOE cells was higher than that of HEY and RMG-II cells.…”

Expressions of Estrogen and Progesterone Receptorsin Epithelial Ovarian Cancer

“…Other studies that attempted to evaluate the prognostic role of ER and PR in combination could not demonstrate an additional benefit of ER+ or ERj expression to the PR+ tumors. 7,11,13,22,26 Different findings on ER/PR expressions and their association with survival in each study might lie on many factors, such as the number of patients studied, the follow-up time, or the heterogeneous patient population wherein some studies included tumors of low malignant potential and others included only patients with advanced-stage diseases. 8,9,12,17 Furthermore, various proportions of tumors with aggressive behavior of clear cell carcinoma or high-grade tumors in these studies may contribute further to the difference.…”

Hormonal therapy in ovarian cancer

“…ER are expressed in 61% to 79% of EOC (71,101,102) . Serous and endometrioid types have the highest ER expression (71,103) .…”